6 articles found
Suzetrigine (Journavx) becomes the first novel non-opioid pain medication approved by FDA in over 20 years, offering surgery patients effective pain relief with significantly lower opioid use.
Scienture Holdings begins shipping REZENOPY, a 10mg naloxone nasal spray—the highest FDA-approved dose—bringing a new overdose reversal option as fentanyl deaths decline nationwide.
FDA cracks down on illegal online ketamine market with 14 warning letters to websites selling non-approved ketamine products for depression and addiction treatment.
DyAnsys Drug Relief receives FDA clearance as a non-narcotic auricular neurostimulation device designed to alleviate opioid withdrawal symptoms during detoxification.
FDA awards priority review vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics for psilocybin and methylone therapies targeting treatment-resistant depression and PTSD.
Flow Neuroscience's transcranial direct current stimulation device becomes first prescription brain stimulation therapy available for home use, offering new option for treatment-resistant depression